Vernal Biosciences provides an end‑to‑end CDMO platform for mRNA and lipid nanoparticle (LNP) production, covering sequence design, custom synthesis, GMP manufacturing, formulation, and analytical services. Their data‑driven Quality‑by‑Design system delivers high‑purity, high‑yield mRNA material—both catalog and custom—scaled from research‑grade to clinical‑grade batches, enabling biotech and pharma companies to accelerate preclinical and clinical development.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
2OACCRFounders
Product
Problem
Researchers and biotech companies developing mRNA therapeutics face unreliable supply chains, variable product quality, and lengthy, costly scale‑up processes that hinder rapid progression from discovery to clinical trials.
Solution
Vernal Biosciences offers an end‑to‑end CDMO platform for mRNA and lipid nanoparticle (LNP) production, covering sequence design, custom synthesis, GMP manufacturing, formulation, and analytical services. By integrating a data‑driven Quality‑by‑Design system, Vernal optimizes codon usage, caps, nucleoside modifications, and purification steps to achieve high‑purity, high‑yield material. The service includes both catalog mRNAs for immediate research use and custom programs that can be scaled from research‑grade to GMP‑compliant clinical batches. Turn‑key manufacturing and analytical support reduce development timelines, improve batch‑to‑batch consistency, and enable rapid translation of mRNA candidates into preclinical and clinical studies.
Target Audience
Primary customers are biotech and pharmaceutical companies, as well as academic research groups, that require reliable, high‑quality mRNA or mRNA‑LNP material for preclinical studies or clinical development.
Features
- Full‑service workflow: sequence design, in‑vitro transcription, capping, poly(A) tailing, purification, and LNP encapsulation
- High‑purity catalog mRNAs (reporter, gene‑editing, gene‑replacement, antigen) with N1‑methyl‑pseudouridine, Cap‑1 structure, optimized codons, and defined poly(A) tails
- Custom mRNA synthesis with data‑driven codon optimization using Vernal’s internal sequence‑performance database
- GMP‑compliant manufacturing and sterile fill‑finish for clinical‑grade material
- Scalable LNP formulation platform with rapid turnaround (e.g., proof‑of‑concept LNPs in ~2 months)
- Integrated analytical suite (purity, integrity, encapsulation efficiency, potency) supporting regulatory submissions
- Quality‑by‑Design (QbDVision) system that captures process data to predict scale‑up outcomes and ensure consistent product quality